Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naltrexone + acetaminophen is a combination of two small molecule drugs. Naltrexone is an opioid receptor antagonist primarily used in the treatment of opioid use disorder and alcohol use disorder, acting by blocking opioid receptors and reducing cravings for opioids and alcohol. Acetaminophen (also known as paracetamol) is a widely used analgesic and antipyretic that works by inhibiting prostaglandin synthesis in the central nervous system, providing pain relief and fever reduction. The combination has been investigated at low doses for acute migraine treatment, with studies suggesting it may provide greater pain relief than placebo. Naltrexone also exhibits anti-inflammatory effects by blocking production of pro-inflammatory cytokines such as interleukin-6, tumor necrosis factor-alpha, interferon-beta, calcitonin gene-related peptide (CGRP), nitric oxide (NO), and reactive oxygen species (ROS) in nerve cells[3][5]. There are no widely marketed brand names or approved products for this specific combination. Both components can affect liver function; caution should be exercised when co-administering due to increased risk of hepatotoxicity[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Naltrexone + Acetaminophen.